21st Century Center of Excellence (COE) Program Graduate School of Medicine, Keio University
Establishment of Individualized Cancer Therapy Based on Comprehensive
Development of Minimally Invasive and Innovative Therapeutic MethodsJapanese Site
KEIO UNIVERSITY
TOP Program member Research Education Link
 
Program member
 
Program member
 
Masahiro Kizaki
Masahiro Kizaki
Affiliation Assistant Professor,
Department of Internal Medicine, Graduate School of Medicine,
Keio University
  Research activities in the COE program
  Identification of the target molecules and development of a novel molecular targeting therapy for hematological malignancies

Hematological malignancies including acute leukemia and multiple myeloma are disorders characterized by the accumulation of neoplastic hematoplastic cells, resulting in aggressive clinical manifestations. The therapeutic approach to these disorders is basically chemotherapy based on the concept of total cell kill. However, severe side effects and complications such as serious infection and bleeding due to anti-cancer drugs are major problems in the clinical settings. These problems occur because anti-cancer agents have effects on both normal and malignant hematopoietic cells. Recent clinical success of all-trans retinoic acid (ATRA) and imatinib mesylate has focused enthusiasm toward molecular targeted therapy. We have actively sought out new agents among natural products, cytokines, and humanized monoclonal antibodies against basic molecules for proliferation of malignant cells with the ability to modify cellular growth by activating unknown gene programs. In addition, we are developing new mice models of hematological malignancies by using a novel system involving immunodeficient mice.
   
 
   
   
Copyright(c)2004 KEIO University. All Rights Reserved.